3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Neuroblastoma
17
Melanoma
3
Glioblastoma
3
Brain Neoplasms
3
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Meningioma
2
Lymphoma
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasm, Residual
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Gliosarcoma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
Specimen Handling
4
Gemcitabine
3
Cyclophosphamide
3
temsirolimus
2
fludarabine
2
Trastuzumab
2
Temozolomide
2
Sirolimus
2
Radiosurgery
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Leucovorin
2
Injections
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Blood Specimen Collection
2
Biopsy
2
Bevacizumab
2
Azacitidine
2
vandetanib
1
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Interleukin-2
×
CNS
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled